Today: 3 December 2025
Subscribe
Browse Tag

Ozempic

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Published November 18, 2025 Summary: Novo Nordisk (NYSE: NVO) remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its
18 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and
17 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

Published: November 12, 2025 Summary: WeightWatchers says it will sell Wegovy in a pill once launched WeightWatchers (WW) plans to carry Novo Nordisk’s oral Wegovy, pending U.S. approval, leaning into consumer preference for pills over injections and differentiating from rivals
12 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Summary: Novo Nordisk’s U.S.-listed shares (NYSE: NVO) traded lower on Friday after the company and Eli Lilly agreed to cut U.S. prices on GLP‑1 medicines to expand access, including under Medicare. The deal introduces near‑term revenue pressure but could lift
7 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Published: November 6, 2025 TL;DR: Novo Nordisk’s U.S.‑listed shares (NYSE: NVO) swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC
6 November 2025
 ·  ·  ·  ·  ·  · 
Go toTop